Protagonist Therapeutics, Inc (PTGX)
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for various diseases. Founded with the aim of harnessing the potential of peptides as targeted and effective treatments, the company primarily advances programs in gastrointestinal and inflammatory diseases, leveraging proprietary peptide delivery platforms.
Company News
Johnson & Johnson and Protagonist Therapeutics released Phase 3 study results for icotrokinra, showing superior skin clearance in psoriasis treatment compared to placebo and competitor drugs, with sustained effectiveness and favorable safety profile.
Protagonist Therapeutics reported Q2 2025 financial results, highlighting progress in clinical pipeline with rusfertide and icotrokinra drug candidates, while experiencing lower-than-expected revenue but maintaining strong cash reserves through 2028.
BESREMi, a FDA-approved treatment for polycythemia vera, is gaining market share due to its potential for better tolerability and lower risk of treatment-related malignancies compared to competitors like ruxolitinib and hydroxyurea.
Protagonist Therapeutics (PTGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.